Scholars Central

Conference abstractPublished 18 Mar 2019

Biosimilars in dermatology-clinical series of cases

Authors: Rodica Olteanu

Colentina Clinical Hospital, Romania

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Biosimilars represent a challenge in the daily clinical practice and they have demonstrated their effi cacy and good tolerance in a context of limited budget. Our health policy and Romanian protocols regarding the biosimilars does not recommend the pharmaceutical-nonmedical switch. Th e medical switch is permitted only by doctor’s prescription. Methods: In our hospital (Colentina Clinical Hospital, Bucharest, Dermatology Department), we treat patients with moderate to severe psoriasis with biologics according to the European and also Romanian Consensus (etanercept, adalimumab, infl iximab, ixekizumab, secukinumab, ustekinumab-originals or biosimilars) in a number of 290 patients on biologic therapy. From these 290 patients, 50 patients (17.24%) - are on biosimilars (Infl ectra, Remsima, Benepali) as they have been registered on the national program for psoriasis. Th e patients (23 women-46% and 27 men-54%) were studied for 12 months (January 2017-December 2017). Results: We compared the biosimilars patients with 50 patients on originals: etanercept (18 patients) and infl iximab (32 patients). From those 50 patients, fi ve dropped out from adverse reactions (tuberculosis, myocardial infarction etc.) and nine were switched because of ineffi cacy. As the remaining 36 patients, they were switched on other biologics (mainly on other biosimilars). For the patients on originals, at 12 months: 13 patients-26% (12 on Remicade and one on Enbrel) developed adverse reactions or lost PASI 50 (one dropped out and 18 were switched mainly on other originals: etanercept, adalimumab, ustekinumab, ixekizumab). Conclusions: Comparing the two groups, we did not fi nd any signifi cant diff erences (26% lost PASI 50 or had adverse reactions on originals and 28% on biosimilars) regarding maintaining the same therapy because of the adverse reactions or ineffi cacy at 12 months. In our study, the biosimilars demonstrated the same behavior as the originals.

Subjects

Dermatology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectDermatology
  • BylineArticles whose byline prints “Rodica Olteanu”